1. Introduction {#sec1}
===============

Head and neck squamous cell carcinoma (HNSCC), including oral squamous cell carcinoma (OSCC), is the sixth most prevalent type of malignancy worldwide and accounts for approximately 8% to 10% of all cancers in Southeast Asia \[[@B1], [@B2]\]. HNSCC-related mortality is mainly caused by cervical lymph node metastasis, and occasionally by distant organ metastasis \[[@B3]\].

The epithelial-mesenchymal transition (EMT) is a process in which epithelial cells lose their polarity and adopt a mesenchymal phenotype \[[@B4]\]. This process is thought to be a critical step in the induction of tumor metastasis and malignancy \[[@B5]\]. Mani et al. demonstrated that induction of EMT results in cells that have stem cell properties and generates cells with properties similar to breast cancer stem cells \[[@B6]\]. Snail, a member of the zinc-finger transcription factor family, is one of the master regulators that promotes EMT and mediates invasiveness as well as metastasis in many different types of malignant tumors \[[@B7], [@B8]\]. The aldehyde dehydrogenase (ALDH) family of enzymes is comprised of cytosolic isoenzymes that oxidize intracellular aldehydes and contribute to the oxidation of retinol to retinoic acid in early stem cell differentiation \[[@B9]\]. Recently, ALDH has been reported to be a unique marker of head and neck cancer stem cells (CSC) \[[@B10], [@B11]\]. ALDH1 was also found to co-localize with other CSCs-related markers, including MMP-9, CD44, and CK14, at the invasive front of the tumor \[[@B12]\]. We previously reported the isolation of ALDH1-positive cells from patients with HNSCC \[[@B13]\]. These HNSCC-ALDH1^+^ cells displayed the radioresistance and represented a reservoir of cells that have the proliferative potential to generate tumors \[[@B13]\]. ALDH1^+^-lineage cells underwent EMT and endogenously co-expressed Snail \[[@B13]\]. These findings suggested that Snail expression may regulate the tumorigenesis, radiochemoresistance, and cancer stem cell properties of malignant HNSCC tumors \[[@B13]\]. However, the molecular mechanisms involved in mediating metastasis and tumor malignancy of HNSCC-CSC through the regulation of Snail remain unknown.

Bmi-1 is a member of the Polycomb (PcG) family of transcriptional repressors that mediate gene silencing by regulating chromatin structure \[[@B14]\]. Bmi-1 is essential for maintaining the ability of neural, hematopoietic, and intestinal stem cells to self-renew \[[@B15]--[@B17]\]. Bmi-1 was identified as a proto-oncogene that cooperates with MYC to promote the generation of lymphoma \[[@B18]\]. Bmi-1 also inhibited MYC-induced apoptosis by repressing the Cdkn2a locus \[[@B19]\]. Additionally, Bmi-1 has been verified as a predictor of prognosis in bladder cancer \[[@B20]\], prostate cancer \[[@B21]\], brain cancer \[[@B22], [@B23]\], breast cancer \[[@B24]\], pancreatic cancer \[[@B25]\], and lung cancer \[[@B26]\]. Bmi-1 has been demonstrated to play a role in the tumorigenesis of HNSCC \[[@B27], [@B28]\]. Bmi-1 has also been reported to be involved in tumor metastasis \[[@B29], [@B30]\]. Recently, an elegant study by Song et al. showed that Bmi-1 can directly promote EMT and malignancy in nasopharyngeal carcinoma by regulating Snail \[[@B31]\]. The goal of this study was to clarify the relationship between Bmi-1, Snail, and ALDH1 in HNSCC or HNSCC-associated CSC and the involved molecular mechanisms.

2. Materials and Methods {#sec2}
========================

2.1. Isolation and Cultivation of HNSCC-Derived ALDH1^+^ and ALDH1^−^ Cells from HNSCC Patients {#sec2.1}
-----------------------------------------------------------------------------------------------

This study followed the tenets of the Declaration of Helsinki. All samples were obtained after patients provided informed consent. The study was approved by the Institutional Ethics Committee/Institutional Review Board of Taipei Veterans General Hospital. The information of HNSCC patients has been previously described in [Table 1](#tab1){ref-type="table"}. The dissociated cells from the samples of HNSCC patients were suspended at 1 × 10^6^ cells/mL in 37°C DMEM supplemented with 2% FCS. The identification of aldehyde dehydrogenase 1 (ALDH1) positive HNSCC cells was carried out using the Aldefluor assay (StemCell Technologies, Durham, NC, USA) and fluorescence-activated cell sorting. Cells were suspended in ALDEFLUOR assay buffer containing ALDH substrate (BAAA, 1 *μ*mol/l per 1 × 10^6^ cells) and incubated for 40 min at 37°C. As a negative control, for each sample of cells, an aliquot was treated with 50 mmol/l diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. The sorting gates were established using the cells stained with PI only as a negative control; the ALDEFLUOR-stained cells treated with DEAB and staining with a secondary antibody alone to test for viability. HNSCC-ALDH1^+^ cells were cultured in a medium consisting of serum-free DMEM/F12 (Gibco-BRL, Gaithersburg, MD), N2 supplement (R and D Systems Inc., Minneapolis), 10 ng/mL bFGF (R and D Systems), and 10 ng/mL EGF (R and D Systems) \[[@B13], [@B32]\].

2.2. Quantitative Real-Time RT-PCR {#sec2.2}
----------------------------------

Briefly, total RNA (1 *μ*g) of each sample was reverse-transcribed using 0.5 *μ*g oligo dT and 200 U Superscript II RT (Invitrogen). The primer sequences for real-time RT-PCR were listed in [Table 2](#tab2){ref-type="table"}. The amplification was carried out in a total volume of 20 *μ*L containing 0.5 *μ*mol·L^−1^ of each primer, 4 mmol·L^−1^ MgCl2, 2 *μ*L LightCyclerTM-FastStart DNA Master SYBR green I (Roche Molecular Systems, Alameda, CA), and 2 *μ*L of 1 : 10 diluted cDNA. PCR reactions were prepared in duplicate and performed using the following program: 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 sec, annealing at 55°C for 5 sec, and extension at 72°C for 20 sec. Standard curves (cycle threshold values versus template concentration) were prepared for each target gene and for the endogenous reference gene (GAPDH) for each sample. Quantification of unknown samples was performed using LightCycler Relative Quantification Software version 3.3 (Roche).

2.3. Knockdown and Overexpression of Bmi-1 with Lentivirus {#sec2.3}
----------------------------------------------------------

The pLVRNAi vector was purchased from Biosettia Inc. (Biosettia, San Diego CA). The oligonucleotide 5′-AAAACCTAATACTTTCCAGATTGATTTGGAT CCAAATCAATCTGGAAAGTATTAGG-3′ targeting human Bmi-1 (NM_005180, nt 1061--1081) was synthesized and cloned into pLVRNAi to generate the lentiviral expression vector, pLVRNAi/sh-Bmi1. The lentiviral expression vector carrying Bmi-1 full-length cDNA, pLV/Bmi-1 was obtained from Biosettia Inc. pCMVΔR8.9 and pMD.G, expressing GAG-POL and the vesicular stomatitis virus envelope, respectively, were provided by the consortium (Academia Sinica, Taipei, Taiwan). The lentiviruses were generated by cotransfecting 5 × 10^6^ 293FT cells per 10 cm plate with lentiviral vector and packaging plasmids using Lipofectamine 2000 (LF2000, Invitrogen). Supernatants were collected 48 hours after transfection and filtered. The 48-hour posttransduction viral titers were determined by FACS. Subconfluent cells were infected with lentivirus at a multiplicity of infection of 5 in the presence of 8 *μ*g/mL polybrene (Sigma-Aldrich) \[[@B13], [@B33]\].

2.4. Microarray Analysis and Bioinformatics {#sec2.4}
-------------------------------------------

Total RNA was extracted from cells using Trizol reagent (Life Technologies, Bethesda, MD, USA) and the Qiagen RNAeasy (Qiagen, Valencia, CA, USA) column for purification. Affymetrix HG U133 Plus 2.0 microarrays containing 54,675 probe sets for \>47,000 transcripts and variants, including 38,500 human genes. A typical probeset contains eleven 25-mer oligo nucleotide pairs (a perfect match and a mismatch control). For microarray analysis, sample labeling, hybridization, and staining were carried out by Affymetrix standard protocol with *affyQCReport*. Probeset was normalized with loess method of all microarrays. The average linkage distance was used to assess the similarity between two groups of gene expression profiles as described below. The difference in distance between two groups of sample expression profiles to a third was assessed by comparing the corresponding average linkage distances (the mean of all pairwise distances (linkages) between members of the two groups concerned). The error of such a comparison was estimated by combining the standard errors (the standard deviation of pairwise linkages divided by the square root of the number of linkages) of the average linkage distances involved. Classical multidimensional scaling (MDS) was performed using the standard function of the R program to provide a visual impression of how the various sample groups are related.

2.5. In Vivo Tumor Growth and Metastasis {#sec2.5}
----------------------------------------

All procedures involving animals were in accordance with the institutional animal welfare guidelines of Taipei Veterans General Hospital. Eight-week-old SCID mice and/or nude mice (BALB/c strain) were injected with 105 cells orthotopically. *In vivo*GFP imaging was performed using an illuminating device (LT-9500 Illumatool/TLS equipped with an excitation source (470 nm) and filter plate (515 nm)). Tumor size was measured with calipers and the tumor volume was calculated using the formula (Length × Width2)/2. The integrated optical density of green fluorescence intensity was captured and analyzed using Image Pro-plus software \[[@B33], [@B34]\].

2.6. Statistical Analysis {#sec2.6}
-------------------------

The Statistical Package of Social Sciences software (SPSS, Inc., Chicago, IL) was used for statistical analysis. An independent Student\'s *t*-test was used to compare the continuous variables between groups. The Kaplan-Meier procedure was used to calculate survival probability estimates. A log-rank test was used to compare the cumulative survival durations in different patient groups. The statistical significance level was set at 0.05 for all tests.

3. Results {#sec3}
==========

3.1. HNSCC-Derived ALDH1-Positive Cells Displayed Tumorigenic and Stemness Properties {#sec3.1}
-------------------------------------------------------------------------------------

Initially, parental, isolated ALDH1^+^, and ALDH1^−^ cells were isolated from tissue samples of six HNSCC patients using the Aldefluor assay and the fluorescence-activated cell sorting (FACS) analysis ([Figure 1(a)](#fig1){ref-type="fig"}and [Table 1](#tab1){ref-type="table"}) \[[@B13], [@B35]\]. It has been reported that cancer stem-like cells can be cultured in suspension to generate floating spheroid-like bodies (SB) under serum-free medium with bFGF and EGF \[[@B36]\]. Interestingly, ALDH1^+^ increased higher tumor spheres-forming capability than that of ALDH1^−^ ([Figure 1(b)](#fig1){ref-type="fig"}). Furthermore, ALDH1^+^-derived spheres with regular 10% serum cultivation increased epithelial-attached cells and differentiation marker (CK18)(See Figure 1(a) in supplementary material available online at doi: 10.1155/2011/609259).To evaluate the enhancement of tumorigenicity of HNSCC-ALDH1^+^ cells, soft agar colony formation assays and Matrigel/Transwell-invasion and were examined. Compared with parental and ALDH1^−^, ALDH1^+^ derived from HNSCC Patients no.1 and no. 2 showed colony-forming ability and higher invasion activity (Figures [1(c)](#fig1){ref-type="fig"}and [1(d)](#fig1){ref-type="fig"}). To evaluate the *in vivo* tumor initiating capability of ALDH1^+^ and ALDH1^−^, we injected 1000, 3000, and 10^4^ cells into the neck of SCID mice. The results showed that 104 ALDH1^−^ did not induce tumor formation but 3,000 ALDH1^+^ from the HNSCC tissues of six patients in xenotransplanted mice all resulted in the generation of visible tumors 6 weeks after injection ([Table 1](#tab1){ref-type="table"}).The results of xenotransplanted analysis further showed that ALDH1^+^ demonstrated higher abilities to induce tumor growth ([Figure 1(e)](#fig1){ref-type="fig"}). Lastly, serial xenotransplanted analysis suggested that ALDH1^+^ had in vivo self-renewal ability (Supplementary Figure 1(b)). Based on these findings, the ALDH1^+^-lineage cells isolated from HNSCC patients presented the significant tumor-initiating abilities, especially in ALDH1^+^ cells from patients no. 1 and no. 2. Real-time RT-PCR data demonstrated that the stemness and EMT-related genes (especially in Bmi-1 and Snail) were significantly activated in HNSCC ALDH1^+^ ([Table 2](#tab2){ref-type="table"}and data not shown).

3.2. Knockdown of Bmi-1 in HNSCC-ALDH1^+^ Cells Down-Regulates Snail and Lessens in vitro Tumorigenicity {#sec3.2}
--------------------------------------------------------------------------------------------------------

To further investigate the role of Bmi-1 in maintaining the biological properties of HNSCC-ALDH1^+^, we used a loss-of-function approach, in which Bmi-1 was knocked down by small hairpin RNA (shRNA) in HNSCC-ALDH1^+^ cells. Stable knockdown of Bmi-1 in HNSCC-ALDH1^+^ cells was achieved by transduction with lentivirus that expressed shRNA targeting Bmi-1 (sh-Bmi-1). Lentivirus that expressed shRNA targeted against luciferase (sh-Luc.) was used as a control. Western blot analysis confirmed that shBmi-1 repressed Bmi-1 protein expression in HNSCC-ALDH1^+^ cells ([Figure 2(a)](#fig2){ref-type="fig"}). Importantly, silencing Bmi-1 expression led to downregulation of Snail and ALDH1 expression ([Figure 2(a)](#fig2){ref-type="fig"}). Additionally, our results showed that silencing of Bmi-1 in HNSCC-ALDH1^+^ cells inhibited the ability of the cells to form colonies on soft agar ([Figure 2(b)](#fig2){ref-type="fig"}) and migrate/invade ([Figure 2(c)](#fig2){ref-type="fig"}).

3.3. Overexpression of Bmi-1 in HNSCC-ALDH1^−^ Cells Enhances Tumorigenic Properties by Upregulating Snail {#sec3.3}
----------------------------------------------------------------------------------------------------------

To evaluate whether overexpression of Bmi-1 could enhance the tumorigenic properties of HNSCC-ALDH1^−^ cells, we generated stable Bmi-1-overexpressing (Bmi-1Over) HNSCCs using lentiviral transduction ([Figure 2(d)](#fig2){ref-type="fig"}). Total proteins from HNSCC-ALDH1**^−^** overexpressing Bmi-1 exhibited elevated expression of Snail and ALDH1 ([Figure 2(d)](#fig2){ref-type="fig"}). In addition, overexpression of Bmi-1 significantly increased soft agar colony formation ([Figure 2(e)](#fig2){ref-type="fig"}), and migration/invasion of HNSCC-ALDH^−^ cells ([Figure 2(f)](#fig2){ref-type="fig"}). Taken together, our results suggest that Bmi-1 modulates the *in vitro* tumorigenic properties in HNSCC-ALDH1^+^ or ALDH1^−^ cells by regulating Snail.

3.4. Overexpression of Bmi-1 in HNSCC-ALDH1^−^ Cells Promotes Stemness Properties {#sec3.4}
---------------------------------------------------------------------------------

To explore molecules governing stemness and tumorigenicity in HNSCC-CD44^−^ALDH1^−^ cells treated with Bmi1-overexpressing lentivirus, we examined their transcriptome profile using gene expression microarray analysis ([Figure 3(a)](#fig3){ref-type="fig"}). Principle component analysis (PCA) further showed that the transcriptome profile of HNSCC-ALDH1^−^ cells overexpressing Bmi-1 demonstrated higher expression levels of embryonic stem cells (ESCs) transcriptomes ([Table 3](#tab3){ref-type="table"}and [Figure 3(b)](#fig3){ref-type="fig"}). Multidimensional scaling analysis further demonstrated that HNSCC-ALDH1^+^ cells and HNSCC-ALDH1^−^ cells overexpressing Bmi-1 are more similar to ESCs than HNSCC-ALDH1^−^ cells (\**P* \< .05; [Figure 3(c)](#fig3){ref-type="fig"}). To validate the microarray analysis results, real-time PCR was performed to confirm that the mRNA expression levels of the embryonic genes (Oct-4, Nanog, Sox2, KLF4, and Lin28), EMT-related genes (Snail and Slug), and drug-resistant-related genes (MDR-1 and ABCG2) in Bmi-1-overexpressing ALDH1^−^ cells were significantly higher than those in ALDH1^−^ cells (\**P* \< .05; [Table 2](#tab2){ref-type="table"}and [Figure 3(d)](#fig3){ref-type="fig"}).

3.5. Elevation of In Vivo Tumor Growth, Metastatic Activity, and Radioresistance in HNSCC-ALDH1^−^ Cells by Overexpression of Bmi-1 {#sec3.5}
-----------------------------------------------------------------------------------------------------------------------------------

We next sought to determine if Bmi-1 expression could modulate the *in vivo* tumor initiating activity in immunocompromised nude mice. To monitor the *in vivo* growth of ALDH1^+^, ALDH1^−^, and Bmi-1-overexpressing ALDH1^−^ cells, these cells were transfected using a lentivector combined with the green fluorescent protein gene (GFP) and followed by *in vivo*GFP imaging system. Firstly, the results showed that 1 × 10^4^ALDH1^−^ cells did not induce tumor formation in nude mice, but 1000 ALDH1^+^ cells generated visible tumors 6 weeks after injection ([Table 1](#tab1){ref-type="table"}). In contrast to ALDH1^−^ cells, one of three (33.3%) nude mice was detected with the tumor formation after 6-week transplantation of 3000 Bmi-1-overexpressing ALDH1^−^ cells. Furthermore, tumor volumes in HNSCC-ALDH1^+^ transplanted mice were significantly decreased when mice were treated with sh-Bmi-1 ([Table 1](#tab1){ref-type="table"}; [Figure 4(a)](#fig4){ref-type="fig"}). Overexpression of Bmi-1 enhanced *in vivo* tumor growth in HNSCC-ALDH1^−^ ([Table 1](#tab1){ref-type="table"}; [Figure 4(a)](#fig4){ref-type="fig"}). Furthermore, we investigated the role of Bmi-1 in the radio sensitivity of HNSCC-ALDH1^−^ and HNSCC-ALDH1^+^ treated with sh-Bmi-1 and Bmi-1 overexpressing. An ionizing radiation (IR) dose of 0 to 10 Gy was applied to these cells, and HNSCC-ALDH1^+^ cells showed greater radioresistance than the ALDH1^−^ cells (*P* \< .05; [Figure 4(b)](#fig4){ref-type="fig"}). Knockdown of BMI-1 in ALDH1^+^ cells results in significant inhibition of radioresistance while overexpression of BMI-1 in ALDH- cells promotes radioresistant properties (*P* \< .05; [Figure 4(b)](#fig4){ref-type="fig"}). Moreover, to confirm that Bmi-1 is crucial for metastasis *in vivo*, mice were injected with different numbers of ALDH1^+^, ALDH1^+^/sh-Bmi-1, ALDH1^−^/Bmi-1over or control GFP-expressing ALDH1^−^ cells. 5x105 Bmi-1-overexpressing ALDH1^−^ cells significantly increased local invasion, distant metastasis to the lungs and tumor size compared with control ALDH1^−^ cells (Figures [5(a)](#fig5){ref-type="fig"}and [5(b)](#fig5){ref-type="fig"}). In addition, silencing Bmi-1 in ALDH1^+^ cells effectively reduced the number of lung metastases and tumor size*in vivo*(Figures [5(a)](#fig5){ref-type="fig"} and [5(b)](#fig5){ref-type="fig"}). Taken together, our results reveal a crucial role for Bmi-1 signaling in the maintenance of *in vivo* tumorigenicity and metastasis of HNSCC-ALDH1^+^ and -ALDH1^−^ cells.

3.6. Coexpression of Bmi-1, Snail, and ALDH1 in HNSCC Tissues Correlates with Poor Overall Survival Rate of HNSCC Patients {#sec3.6}
--------------------------------------------------------------------------------------------------------------------------

Elevated Snail protein expression in HNSCC is correlated with the development of metastasis and poor survival \[[@B37]\]. Elevated expression of ALDH1 also correlates with poor prognosis for HNSCC patients \[[@B13]\]. To investigate whether there is a positive correlation between Bmi-1, Snail, and ALDH1 in head and neck cancers, we studied the expression of Bmi-1, Snail, and ALDH1 by immunohistochemical (IHC) staining of a panel of specimens array from 93 HNSCC patients. The IHC results showed that elevated expression of Bmi-1, Snail, and ALDH1 was positively associated with high-grade, poorly differentiated HNSCC ([Figure 6(a)](#fig6){ref-type="fig"}). Our results also showed a significant positive correlation between ALDH-1, Bmi-1 ([Figure 6(b)](#fig6){ref-type="fig"}); ALDH-1 and Snail ([Figure 6(c)](#fig6){ref-type="fig"}); Bmi-1 and Snail ([Figure 6(d)](#fig6){ref-type="fig"}) in HNSCC tissues. This is consistent with previous studies that reported that HNSCC-ALDH1^+^ cells have elevated Bmi-1 and Snail expression \[[@B13], [@B38]\]. To determine the prognostic significance of Bmi-1, Snail, and ALDH1 coexpression in patients with HNSCC, Kaplan-Meier survival analysis was performed. Patients who were triple positive for Bmi-1, Snail, and ALDH1 were predicted to have the worst survival rate compared with other head and neck cancer patients ([Figure 6(e)](#fig6){ref-type="fig"}; Bmi-1^+^/Snail^+^/ALDH1^+^ versus other groups). Overall, these data indicate that expression of Bmi-1, Snail, and ALDH1 in HNSCC patients could be a critical factor in predicting disease progression and clinical outcomes.

4. Discussion {#sec4}
=============

A recent study demonstrated that Bmi-1 mRNA and protein overexpressed in a subpopulation of tumor initiating cells in CD44+ HNSCC, which possessed self-renewal and tumor formation ability \[[@B39]\]. Zhang et al. also reported that there are side populations of oral squamous cell carcinomas that express high levels of ABCG2, ABCB1, CD44, Oct-4, Bmi-1, NSPc1, and CK19 \[[@B28]\]. Our previous work showed that HNSCC-ALDH1+ cells have high levels of Bmi-1. The ability to self-renew and radiochemoresistance were significantly suppressed in Bmi-1-silenced HNSCC-ALDH1+ cells \[[@B38]\]. Using microarray, western-blotting, and immunofluorescent assays, Chen et al. confirmed that ALDH1+-lineage cells underwent epithelial-mesenchymal transition (EMT) and endogenously co-expressed Snail \[[@B13]\]. In the current study, our data demonstrated that HNSCC-ALDH1^+^ cells had high levels of Bmi-1, at both the mRNA and protein levels ([Figure 2](#fig2){ref-type="fig"}). Using a lentiviral vector expressing shRNA targeting Bmi-1, we observed that the level of ALDH1 expression and tumorigenic properties of HNSCC-ALDH1^+^ could be down-regulated by knockdown of Bmi-1 ([Figure 2](#fig2){ref-type="fig"}). Importantly, overexpression of Bmi-1 could turn HNSCC-ALDH1^−^ into cancer stem cell-like HNSCC-ALDH1^+^ cells ([Figure 3](#fig3){ref-type="fig"}). Consistent with these findings, the immunohistochemical survey of 93 HNSCC patient tissues showed a positive correlation between expression of Bmi-1, Snail, or ALDH1 and tumor stage ([Figure 6](#fig6){ref-type="fig"}). Similar results were noted in other malignancies \[[@B40]\]. Kaplan-Meier analysis demonstrated that patients expressing Bmi-1, Snail, and ALDH1 were predicted to have the worst survival prognosis of HNSCC patients ([Figure 6(e)](#fig6){ref-type="fig"}). However, a recent study showed a significant correlation between negative Bmi-1 protein expression and the recurrence of tongue cancer. Their results showed Snail and c-myc expression did not correlate with prognosis \[[@B41]\]. The divergence from our results may be due to the different pathophysiology of HNSCC. Most HNSCC patients in Taiwan consume alcohol, chew betel quid and smoke cigarettes. Tongue cancer patients, especially female tongue cancer patients, usually do not have these habits \[[@B3]\]. The close relationship between tongue cancer and human papillomavirus has been explored by many researchers \[[@B42]--[@B45]\]. The correlation between cancer stem cells and the virus infection remains to be discovered.

The prognosis of HNSCC patients with distant metastases in the lung, liver, and bone is very poor \[[@B3], [@B46]\]. In this study, we found that Bmi-1 can regulate Snail and ALDH1; change the EMT-related genotypes of the ALDH1^−^ cells; and modulate distant lung metastases ([Figure 5](#fig5){ref-type="fig"}). Distant metastases have been reported to be associated with Bmi-1 expression in breast cancer \[[@B47]--[@B49]\], melanoma \[[@B50]\], gastric cancer \[[@B51]\], and colon cancer \[[@B30]\]. Microarray analysis revealed that eleven gene signatures, which were correlated to the Bmi-1-driven pathway, were closely related to distant lung metastases \[[@B40]\]. Bmi-1 is the target gene of SALL4 in human hematopoietic as well as leukemic cells and is down-regulated if SALL4 is knocked down by the siRNA in the HL-60 leukemia cell line \[[@B52], [@B53]\]. Recently, researchers employed microRNA profiling to gain insight into the role of Bmi-1 in regulating EMT. Overexpression of miR-200c decreased Bmi-1 expression in breast cancer stem cells (BCSCs) and inhibited the formation of mammary ducts as well as tumors by normal mammary stem cells and BCSCs \[[@B54]\]. Bhattacharya et al. found that miR-15a and miR-16 directly targeted the Bmi-1 3′ untranslated region and correlated with Bmi-1 protein levels in ovarian cancer patients and cell lines \[[@B55]\]. Further research effort is needed in this area. Together, our research shows that the Bmi-1 signaling pathways play a major role in the maintenance of stemness and the metastatic ability of HNSCC-CSC by regulating of Snail expression. Additionally, we demonstrate coexpression of Bmi-1, Snail, and ALDH1 in HNSCC patients was positively correlated with tumor grade and the worst prognosis.
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Figure 1. (a) Cell morphology in ALDH1+ HNSCC cells under specific serum free medium and 10% serum (right panel). Epithelial differentiation marker, CK18 positive cells in ALDH1+ HNSCC cells under specific serum free medium and 10% serum (right panel). (b) In vivo self-renewal ability of HNSCC-ALDH1+ cells.
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Click here for additional data file.
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![Isolation and Characterization of HNSCC-derived ALDH1-positive Cells. (a) Analyzing and sorting ALDH1^+^-positive and ALDH1^−^-negative from HNSCC tissues via FACScan. DEAB, an inhibitor of ALDH1, was used for negative control. (b) Evaluation of sphere body formation in the parental cells, ALDH1^−^ cells, and ALDH1^+^cells. Sphere bodies were counted after 1 week. The numbers of resultant colonies (c) and invasion cells (d) from parental cells, ALDH1^+^ cells, and ALDH1^−^cells were counted*in vitro*. (e) Macroscopic features of cells in a nude mouse at 6 weeks after xenotransplantation. Blue arrow indicates the site of injection of ALDH1^−^cells. Red arrow indicates the site of injection of ALDH1^+^cells. Yellow arrow indicates the site of injection of ALDH1^+^cells. \**P* \< .05. Data shown here are the mean ± SD of three experiments.](JO2011-609259.001){#fig1}

![Overexpression of Bmi-1 in HNSCC-ALDH1^−^ cells or knockdown of Bmi-1 in HNSCC-ALDH^+^ cells modulates Snail expression and tumorigenicity*in vitro*. (a) Down-regulation of Bmi-1 mediated by lentiviral shRNA and expression of Snail and ALDH1 in HNSCC-ALDH1^+^ cells was analyzed by western blot. Colony formation (b) and migration/invasion ability (c) of shLuc.-expressing and shBmi-1-expressing HNSCC-ALDH1^+^cells was determined. (d) Total protein was prepared from control GFP--expressing andBmi-1-overexpressing HNSCC-ALDH1^−^ cells and analyzed by immunoblotting with anti-Bmi-1, anti-Snail, anti-ALDH1, or anti-GAPDH antibodies as indicated. The amount of GAPDH protein from each crude cell extract was used as loading control. Colony formation (e) and migration/invasion ability (f) of Bmi-1-overexpressing and control-GFP-expressing HNSCC-ALDH1^−^ were analyzed. \**P* \< .05. Data shown here are the mean ± SD of three experiments.](JO2011-609259.002){#fig2}

![Stemness properties were enhanced in HNSCC-ALDH1^−^ cells when Bmi-1 was overexpressed. (a) Gene expression microarray analysis (Gene tree) for altered genes differentially expressed in Bmi-1-overexpressing HNSCC-ALDH1^−^ cells compared to HNSCC-ALDH1^−^ cells by a hierarchy heat map. The time dependent changes of altered genes are presented on a log scale of expression values provided by GeneSpring GX software. (b) Principle component analysis (PCA) demonstrated that overexpression of Bmi-1 in HNSCC-ALDH1^−^ cells could enhance the gene signature of embryonic stem cells (ESCs) in HNSCC-ALDH1^−^ cells. (c) Multidimensional scaling analysis. Average lineage transcriptome distances between HNSCC-ALDH1^+^, HNSCC-ALDH1^−^, HNSCC-ALDH1^+^/sh-Bmi-1, and HNSCC-ALDH1^−^/Bmi1^over^ cells. \**P* \< .05. (d) Transcripts of Oct-4, Nanog, Sox2, KLF4, Lin28, Snail, Slug, MDR-1, and ABCG2 in HNSCC-ALDH1^−^ and HNSCC-ALDH1^−^/Bmi-1^over^ cells (\**P* \< .05: ALDH1^−^ versus Bmi-1-overexpressing ALDH1^−^).](JO2011-609259.003){#fig3}

![Determination of the role of Bmi-1 on *in vivo* tumor growth and radioresistance in HNSCC-ALDH1^+^cells. (a) Tumor volume was measured after injection of either HNSCC-ALDH1^+^, sh-Bmi-1 treated HNSCC-ALDH1^+^, HNSCC-ALDH1**^−^**, or Bmi-1-overexpressing HNSCC- ALDH1**^−^** cells into the neck of SCID mice. Error bars correspond to SD. (b) To determine the radiation effect on the cell survival rate, an ionizing radiation (IR) dose from 0 to 10Gy was used to treated with ALDH1^+^/vector, ALDH1^+^/sh-Bmi-1, ALDH1**^−^** /vector, or Bmi-1-overexpressing HNSCC- ALDH1**^−^** HNSCC cells.](JO2011-609259.004){#fig4}

![Elimination of metastatic activity in HNSCC-ALDH1^+^cells treated with shBmi-1. (a) Summary of the *in vivo* metastasis ability of different numbers of HNSCC-ALDH1^+^, sh-Bmi-1 treated HNSCC-ALDH1^+^, HNSCC- ALDH1**^−^**, or Bmi-1-overexpressing HNSCC- ALDH1**^−^** cells examined by xenotransplantation analysis. (b) The average numbers of metastatic foci (*left panel*) and total weight (*right panel*) in the lungs of mice treated with either HNSCC-ALDH1^+^, sh-Bmi-1 treated HNSCC-ALDH1^+^, HNSCC- ALDH1**^−^**, or Bmi-1-overexpressing HNSCC-ALDH1**^−^**cells are shown. (\**P* \< .05: ALDH1^−^ versus Bmi-1-overexpressing ALDH1^−^; ^\#^ *P* \< .05: ALDH1^+^ versus shBmi-1 treated HNSCC-ALDH1^+^).](JO2011-609259.005){#fig5}

![Coexpression of Bmi-1, Snail, and ALDH1 in HNSCC patient specimen and prediction of survival of the HNSCC patients. (a) Representative pictures of triple positive (*upper panel*) and triple negative (*lower panel*) HNSCC cases. Coexpression of Bmi-1 and ALDH1 (b), Bmi-1 and Snail (c) or Snail and Bmi-1 (d) of 93 HNSCC patient samples were examined immunohistochemically. (e) Kaplan-Meier analysis of overall survival of HNSCC patients according to expression of ALDH1 (+) Bmi-1 (+) Snail (+), ALDH1 (+) Bmi-1 (+) Snail (−), ALDH1 (−) Bmi-1 (+) Snail (+) or ALDH1 (−) Bmi-1 (−) Snail (−). (\*, *P* \< .05; \*\*, *P* \< .01; \*\*\*, *P* \< .001).](JO2011-609259.006){#fig6}

###### 

Case description, tumorigenic characteristics and treatment effects of ALDH1^+^ and ALDH1^−^ HNSCC.

                            Number of cells injected                                                
  --- -------- ------ ----- -------------------------- -------------- -------------- -------------- --------------
  1   71/ M    44.2   Yes   1,000 (0/3)                1,000 (1/3)    1,000 (0/3)    1,000 (0/3)    1,000 (1/3)
                            3,000 (0/3)                3,000 (3/3)    3,000 (0/3)    3,000 (0/3)    3,000 (1/3)
                            10,000 (1/3)               10,000 (3/3)   10,000 (2/3)   10,000 (1/3)   10,000 (2/3)
                                                                                                    
  2   73/ F    24.7   Yes   1,000 (0/3)                1,000 (1/3)    1,000 (1/3)    1,000 (0/3)    1,000 (0/3)
                            3,000 (0/3)                3,000 (2/3)    3,000 (2/3)    3,000 (0/3)    3,000 (1/3)
                            10,000 (2/3)               10,000 (2/3)   10,000 (2/3)   10,000 (0/3)   10,000 (2/3)
                                                                                                    
  3   61 / F   8.6    Yes   1,000 (0/3)                1,000 (1/3)    1,000 (1/3)    1,000 (0/3)    1,000 (0/3)
                            3,000 (0/3)                3,000 (3/3)    3,000 (1/3)    3,000 (0/3)    3,000 (2/3)
                            10,000 (0/3)               10,000 (3/3)   10,000 (2/3)   10,000 (0/3)   10,000 (3/3)
                                                                                                    
  4   71 / M   1.2    Yes   1,000 (0/3)                1,000 (0/3)    1,000 (0/3)    1,000 (0/3)    1,000 (0/3)
                            3,000 (0/3)                3,000 (3/3)    3,000 (0/3)    3,000 (0/3)    3,000 (2/3)
                            10,000 (0/3)               10,000 (3/3)   10,000 (2/3)   10,000 (0/3)   10,000 (3/3)
                                                                                                    
  5   69 / M   19.2   Yes   1,000 (0/3)                1,000 (1/3)    1,000 (0/3)    1,000 (0/3)    1,000 (0/3)
                            3,000 (0/3)                3,000 (3/3)    3,000 (1/3)    3,000 (0/3)    3,000 (2/3)
                            10,000 (1/3)               10,000 (3/3)   10,000 (2/3)   10,000 (0/3)   10,000 (3/3)
                                                                                                    
  6   72 / M   5.5    Yes   1,000 (0/3)                1,000 (1/3)    1,000 (0/3)    1,000 (0/3)    1,000 (0/3)
                            3,000 (0/3)                3,000 (3/3)    3,000 (1/3)    3,000 (0/3)    3,000 (2/3)
                            10,000 (0/3)               10,000 (3/3)   10,000 (1/3)   10,000 (0/3)   10,000 (2/3)

ALDH1^+^: ALDH1-positive HNSCC cells; ALDH1^−^: ALDH1-negative HNSCC cells.

ALDH1^+^ or ALDH1^+^cells were injected into neck of SCID mice.

###### 

The sequences for the primers of quantitative RT-PCR.

  Gene(Accession No.)            Primer Sequence (5′ to 3′)     Product size (bp)   Tm (°C)
  ------------------------------ ------------------------------ ------------------- ---------
  Oct-4(NM_002701)               F: GTGGAGAGCAACTCCGATG         86                  60
  R: TGCTCCAGCTTCTCCTTCTC                                                           
                                                                                    
  Nanog(NM_024865)               F: ATTCAGGACAGCCCTGATTCTTC     76                  60
  R: TTTTTGCGACACTCTTCTCTGC                                                         
                                                                                    
  SOX-2(NM_003106)               F: CGAGTGGAAACTTTTGTCGGA       74                  60
  R: TGTGCAGCGCTCGCAG                                                               
                                                                                    
  Musashi(NM_002442)             F: TCCCTCGGCGAGCACA            64                  60
  R: GACAGCCCCCCCACAAA                                                              
                                                                                    
  c-Myc(NM_002467)               F: GGAACGAGCTAAAACGGAGCT       71                  55
  R: GGCCTTTTCATTGTTTTCCAACT                                                        
                                                                                    
  *β*-catenin(NM_001904)         F: CCAGCCGACACCAAGAAG          130                 55
  R: CGAATCAATCCAACAGTAGCC                                                          
                                                                                    
  Bmi1(NM\_ 005180)              F`：`AAATGCTGGAGAACTGGAAAG     124                 50
  R`：`CTGTGGATGAGGAGACTGC                                                          
                                                                                    
  Nestin(NM_006617)              F: AGGAGGAGTTGGGTTCTG          112                 50
  R: GGAGTGGAGTCTGGAAGG                                                             
                                                                                    
  Snail(NM_005985)               F:GCTGCCAATGCTCATCTGGGACTCT    300                 55
  R: TTGAAGGGCTTTCGAGCCTGGAGAT                                                      
                                                                                    
  Slug(NM_003068)                F: GTGATTATTTCCCCGTATCTCTAT    292                 50
  R: CAATGGCATGGGGGTCTGAAAG                                                         
                                                                                    
  MDR-1 (NM_000927)              F: TGGCAAAGAAATAAAGCGACTGA     76                  60
  R: CAGGATGGGCTCCTGGG                                                              
                                                                                    
  MRP-1(X60111)                  F: GCTTCCTCTTGGTGATATTCG       176                 50
  R: GCAGTTCAACGCATAGTGG                                                            
                                                                                    
  ABCG2(NM_004827)               F: CATGTACTGGCGAAGAATATTTGGT   74                  60
  R: CACGTGATTCTTCCACAAGCC                                                          
                                                                                    
  GAPDH(NM_002046)               F: CATCATCCCTGCCTCTACTG        180                 60
  R: GCCTGCTTCACCACCTTC                                                             

###### 

The expression profiling of up-regulated genes in ALDH1^−^/Bmi1-overexpressed as compared to ALDH1^−^ HNSCC.

  Probe set ID    Gene symbol       Gene title
  --------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  217757_at       A2M               alpha-2-macroglobulin
  209459_s\_at    ABAT              4-aminobutyrate aminotransferase
  213353_at       ABCA5             ATP-binding cassette, sub-family A (ABC1), member 5
  209993_at       ABCB1(MDR1)       ATP-binding cassette, sub-family B (MDR/TAP), member 1
  214033_at       ABCC6             ATP-binding cassette, sub-family C (CFTR/MRP), member 6
  210246_s\_at    ABCC8             ATP-binding cassette, sub-family C (CFTR/MRP), member 8
  204567_s\_at    ABCG1             ATP-binding cassette, sub-family G (WHITE), member 1
  209735_at       ABCG2             ATP-binding cassette, sub-family G (WHITE), member 2
  204151_x\_at    AKR1C1            aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)
  209699_x\_at    AKR1C2            aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)
  212224_at       ALDH1A1           aldehyde dehydrogenase 1 family, member A1
  204446_s\_at    ALOX5             arachidonate 5-lipoxygenase
  205216_s\_at    APOH              apolipoprotein H (beta-2-glycoprotein I)
  39248_at        AQP3              aquaporin 3 (Gill blood group)
  218501_at       ARHGEF3           Rho guanine nucleotide exchange factor (GEF) 3
  219087_at       ASPN              Aspirin
  201242_s\_at    ATP1B1            ATPase, Na+/K+ transporting, beta 1 polypeptide
  200921_s\_at    BTG1              B-cell translocation gene 1, anti-proliferative
  228067_at       C2orf55           chromosome 2 open reading frame 55
  206488_s\_at    CD36              CD36 molecule (thrombospondin receptor)
  208783_s\_at    CD46              CD46 molecule, complement regulatory protein
  1553970_s\_at   CEL               carboxyl ester lipase (bile salt-stimulated lipase)
  203854_at       CFI               complement factor I
  205043_at       CFTR              cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)
  204260_at       CHGB              chromogranin B (secretogranin 1)
  221188_s\_at    CIDEB             cell death-inducing DFFA-like effector b
  203953_s\_at    CLDN3             claudin 3
  221042_s\_at    CLMN              calmin (calponin-like, transmembrane)
  1567081_x\_at   CLN6              ceroid-lipofuscinosis, neuronal 6, late infantile, variant
  208791_at       CLU               Clusterin
  229831_at       CNTN3             contactin 3 (plasmacytoma associated)
  205615_at       CPA1              carboxypeptidase A1 (pancreatic)
  206212_at       CPA2              carboxypeptidase A2 (pancreatic)
  205509_at       CPB1              carboxypeptidase B1 (tissue)
  201117_s\_at    CPE               carboxypeptidase E
  224829_at       CPEB4             cytoplasmic polyadenylation element binding protein 4
  204920_at       CPS1              carbamoyl-phosphate synthetase 1, mitochondrial
  201990_s\_at    CREBL2            cAMP responsive element binding protein-like 2
  205971_s\_at    CTRB1 /// CTRB2   chymotrypsinogen B1 /// chymotrypsinogen B2
  214411_x\_at    CTRB2             chymotrypsinogen B2
  209774_x\_at    CXCL2             chemokine (C-X-C motif) ligand 2
  205765_at       CYP3A5            cytochrome P450, family 3, subfamily A, polypeptide 5
  228391_at       CYP4V2            cytochrome P450, family 4, subfamily V, polypeptide 2
  228739_at       CYS1              cystin 1
  222925_at       DCDC2             doublecortin domain containing 2
  205311_at       DDC               dopa decarboxylase (aromatic L-amino acid decarboxylase)
  210397_at       DEFB1             defensin, beta 1
  221081_s\_at    DENND2D           DENN/MADD domain containing 2D
  214787_at       DENND4A           DENN/MADD domain containing 4A
  205684_s\_at    DENND4C           DENN/MADD domain containing 4C
  214079_at       DHRS2             dehydrogenase/reductase (SDR family) member 2
  222850_s\_at    DNAJB14           DnaJ (Hsp40) homolog, subfamily B, member 14
  225415_at       DTX3L             deltex 3-like (Drosophila)
  225645_at       EHF               Ets homologous factor
  210080_x\_at    ELA3A             elastase 3A, pancreatic
  201510_at       ELF3              E74-like factor 3 (ets domain transcription factor, epithelial-specific)
  206191_at       ENTPD3            ectonucleoside triphosphate diphosphohydrolase 3
  220012_at       ERO1LB            ERO1-like beta (S. cerevisiae)
  210103_s\_at    FOXA2             forkhead box A2
  235201_at       FOXP2             forkhead box P2
  226847_at       FST               Follistatin
  205674_x\_at    FXYD2             FXYD domain containing ion transport regulator 2
  205890_s\_at    GABBR1 /// UBD    gamma-aminobutyric acid (GABA) B receptor, 1 /// ubiquitin D
  205848_at       GAS2              growth arrest-specific 2
  216733_s\_at    GATM              glycine amidinotransferase (L-arginine:glycine amidinotransferase)
  204965_at       GC                group-specific component (vitamin D binding protein)
  219508_at       GCNT3             glucosaminyl (N-acetyl) transferase 3, mucin type
  225853_at       GNPNAT1           glucosamine-phosphate N-acetyltransferase 1
  212950_at       GPR116            G protein-coupled receptor 116
  212070_at       GPR56             G protein-coupled receptor 56
  203924_at       GSTA1             glutathione S-transferase A1
  221942_s\_at    GUCY1A3           guanylate cyclase 1, soluble, alpha 3
  228697_at       HINT3             histidine triad nucleotide binding protein 3
  209558_s\_at    HIP1R             huntingtin interacting protein 1 related
  207062_at       IAPP              islet amyloid polypeptide
  213620_s\_at    ICAM2             intercellular adhesion molecule 2
  203828_s\_at    IL32              interleukin 32
  205945_at       IL6R              interleukin 6 receptor
  206598_at       INS               Insulin
  226535_at       ITGB6             integrin, beta 6
  226189_at       ITGB8             integrin, beta 8
  210078_s\_at    KCNAB1            potassium voltage-gated channel, shaker-related subfamily, beta member 1
  219564_at       KCNJ16            potassium inwardly-rectifying channel, subfamily J, member 16
  205303_at       KCNJ8             potassium inwardly-rectifying channel, subfamily J, member 8
  212531_at       LCN2              lipocalin 2
  235970_at       LCORL             ligand dependent nuclear receptor corepressor-like
  1554006_a\_at   LLGL2             lethal giant larvae homolog 2 (Drosophila)
  225996_at       LONRF2            LON peptidase N-terminal domain and ring finger 2
  242931_at       LONRF3            LON peptidase N-terminal domain and ring finger 3
  226748_at       LYSMD2            LysM, putative peptidoglycan-binding, domain containing 2
  213975_s\_at    LYZ               lysozyme (renal amyloidosis)
  222670_s\_at    MAFB              v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)
  223577_x\_at    MALAT1            metastasis associated lung adenocarcinoma transcript 1 (non-protein coding)
  220945_x\_at    MANSC1            MANSC domain containing 1
  204388_s\_at    MAOA              monoamine oxidase A
  235077_at       MEG3              maternally expressed 3
  229254_at       MFSD4             major facilitator superfamily domain containing 4
  219797_at       MGAT4A            mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A
  204259_at       MMP7              matrix metallopeptidase 7 (matrilysin, uterine)
  227747_at       MPZL3             myelin protein zero-like 3
  204438_at       MRC1 /// MRC1L1   mannose receptor, C type 1 /// mannose receptor, C type 1-like 1
  203037_s\_at    MTSS1             metastasis suppressor 1
  212093_s\_at    MTUS1             mitochondrial tumor suppressor 1
  213693_s\_at    MUC1              mucin 1, cell surface associated
  213375_s\_at    N4BP2L1           NEDD4 binding protein 2-like 1
  220184_at       NANOG             Nanog homeobox
  209107_x\_at    NCOA1             nuclear receptor coactivator 1
  1556057_s\_at   NEUROD1           neurogenic differentiation 1
  206915_at       NKX2-2            NK2 homeobox 2
  225911_at       NPNT              Nephronectin
  205259_at       NR3C2             nuclear receptor subfamily 3, group C, member 2
  212768_s\_at    OLFM4             olfactomedin 4
  203845_at       PCAF              p300/CBP-associated factor
  240317_at       PCDHB4            protocadherin beta 4
  212593_s\_at    PDCD4             programmed cell death 4 (neoplastic transformation inhibitor)
  213228_at       PDE8B             phosphodiesterase 8B
  225207_at       PDK4              pyruvate dehydrogenase kinase, isozyme 4
  205380_at       PDZK1             PDZ domain containing 1
  1553589_a\_at   PDZK1IP1          PDZK1 interacting protein 1
  226459_at       PIK3AP1           phosphoinositide-3-kinase adaptor protein 1
  220954_s\_at    PILRB             paired immunoglobulin-like type 2 receptor beta
  219584_at       PLA1A             phospholipase A1 member A
  206311_s\_at    PLA2G1B           phospholipase A2, group IB (pancreas)
  221529_s\_at    PLVAP             plasmalemma vesicle associated protein
  205912_at       PNLIP             pancreatic lipase
  211766_s\_at    PNLIPRP2          pancreatic lipase-related protein 2
  208286_x\_at    POU5F1(Oct4)      POU class 5 homeobox 1 /// POU class 5 homeobox 1B /// POU class 5 homeobox 1 pseudogene 3 /// POU class 5 homeobox 1 pseudogene 4
  228469_at       PPID              Peptidylprolyl isomerase D (cyclophilin D)
  210670_at       PPY               pancreatic polypeptide
  242482_at       PRKAR1A           protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1)
  227629_at       PRLR              Prolactin receptor
  228656_at       PROX1             prospero homeobox 1
  205869_at       PRSS1             protease, serine, 1 (trypsin 1)
  205402_x\_at    PRSS2             protease, serine, 2 (trypsin 2)
  213421_x\_at    PRSS3             protease, serine, 3
  203317_at       PSD4              pleckstrin and Sec7 domain containing 4
  203029_s\_at    PTPRN2            protein tyrosine phosphatase, receptor type, N polypeptide 2
  219562_at       RAB26             RAB26, member RAS oncogene family
  226436_at       RASSF4            Ras association (RalGDS/AF-6) domain family member 4
  223322_at       RASSF5            Ras association (RalGDS/AF-6) domain family member 5
  235638_at       RASSF6            Ras association (RalGDS/AF-6) domain family member 6
  204364_s\_at    REEP1             receptor accessory protein 1
  209752_at       REG1A             regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread protein)
  205886_at       REG1B             regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein)
  205815_at       REG3A             regenerating islet-derived 3 alpha
  1554003_at      RGNEF             Rho-guanine nucleotide exchange factor
  219263_at       RNF128            ring finger protein 128
  221614_s\_at    RPH3AL            rabphilin 3A-like (without C2 domains)
  213939_s\_at    RUFY3             RUN and FYVE domain containing 3
  210592_s\_at    SAT1              spermidine/spermine N1-acetyltransferase 1
  203408_s\_at    SATB1             SATB homeobox 1
  204035_at       SCG2              secretogranin II (chromogranin C)
  205697_at       SCGN              secretagogin, EF-hand calcium binding protein
  229620_at       SEPP1             Selenoprotein P, plasma, 1
  202833_s\_at    SERPINA1          serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
  202376_at       SERPINA3          serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
  209443_at       SERPINA5          serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5
  213572_s\_at    SERPINB1          serpin peptidase inhibitor, clade B (ovalbumin), member 1
  227627_at       SGK3              serum/glucocorticoid regulated kinase family, member 3
  219256_s\_at    SH3TC1            SH3 domain and tetratricopeptide repeats 1
  204019_s\_at    SH3YL1            SH3 domain containing, Ysc84-like 1 (S. cerevisiae)
  213464_at       SHC2              SHC (Src homology 2 domain containing) transforming protein 2
  205799_s\_at    SLC3A1            solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine, dibasic and neutral amino acid transport), member 1
  223044_at       SLC40A1           solute carrier family 40 (iron-regulated transporter), member 1
  228221_at       SLC44A3           solute carrier family 44, member 3
  213139_at       SNAI2(Slug)       snail homolog 2 (Drosophila)
  1560228_at      SNAI3(Snail)      snail homolog 3 (Drosophila)
  213721_at       SOX2              SRY (sex determining region Y)-box 2
  200795_at       SPARCL1           SPARC-like 1 (mast9, hevin)
  206239_s\_at    SPINK1            serine peptidase inhibitor, Kazal type 1
  213921_at       SST               somatostatin
  216905_s\_at    ST14              suppression of tumorigenicity 14 (colon carcinoma)
  230285_at       SVIP              small VCP/p97-interacting protein
  227134_at       SYTL1             synaptotagmin-like 1
  202286_s\_at    TACSTD2           tumor-associated calcium signal transducer 2
  205513_at       TCN1              transcobalamin I (vitamin B12 binding protein, R binder family)
  203887_s\_at    THBD              thrombomodulin
  209937_at       TM4SF4            transmembrane 4 L six family member 4
  226403_at       TMC4              transmembrane channel-like 4
  223503_at       TMEM163           transmembrane protein 163
  218345_at       TMEM176A          transmembrane protein 176A
  220532_s\_at    TMEM176B          transmembrane protein 176B
  200847_s\_at    TMEM66            transmembrane protein 66
  202687_s\_at    TNFSF10           tumor necrosis factor (ligand) superfamily, member 10
  203824_at       TSPAN8            tetraspanin 8
  229169_at       TTC18             tetratricopeptide repeat domain 18
  209660_at       TTR               transthyretin (prealbumin, amyloidosis type I)
  231008_at       UNC5CL            Unc-5 homolog C (C. elegans)-like
  226344_at       ZMAT1             zinc finger, matrin type 1
  206059_at       ZNF91             zinc finger protein 91
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